Skip Navigation

JNCI Monographs 2005 2005(34):25-27; doi:10.1093/jncimonographs/lgi018
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Sklar, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sklar, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

2005 © Oxford University Press

Maintenance of Ovarian Function and Risk of Premature Menopause Related to Cancer Treatment

Charles Sklar

Correspondence to: Charles Sklar, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021 (e-mail: sklarc{at}mskcc.org).

Ovarian damage following cancer therapy is dependent on age at treatment as well as the type of therapeutic exposures. Older age and exposure to higher doses of alkylating agents and higher doses of radiation to the ovary are associated with a greater likelihood of ovarian failure. Acute loss of ovarian function during or shortly following treatment is relatively uncommon in females treated during childhood and adolescence but can be seen following myeloablative, alkylator-based cytoreduction (e.g., busulfan and cyclophosphamide) for stem cell transplant and following direct ovarian radiation with doses >10 Gy. For survivors who retain normal ovarian function after cancer therapy, there is an increased risk of premature menopause later in life. The risk factors associated with an early menopause include exposure to high doses of alkylating agents and abdomino-pelvic radiation.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
P. D. Inskip, L. L. Robison, M. Stovall, S. A. Smith, S. Hammond, A. C. Mertens, J. A. Whitton, L. Diller, L. Kenney, S. S. Donaldson, et al.
Radiation Dose and Breast Cancer Risk in the Childhood Cancer Survivor Study
J. Clin. Oncol., August 20, 2009; 27(24): 3901 - 3907.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. M. Green, C. A. Sklar, J. D. Boice Jr, J. J. Mulvihill, J. A. Whitton, M. Stovall, and Y. Yasui
Ovarian Failure and Reproductive Outcomes After Childhood Cancer Treatment: Results From the Childhood Cancer Survivor Study
J. Clin. Oncol., May 10, 2009; 27(14): 2374 - 2381.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
S. Lie Fong, J.S.E. Laven, F.G.A.J. Hakvoort-Cammel, I. Schipper, J.A. Visser, A.P.N. Themmen, F.H. de Jong, and M.M. van den Heuvel-Eibrink
Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone
Hum. Reprod., April 1, 2009; 24(4): 982 - 990.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. L. Friedman, A. Rovo, W. Leisenring, A. Locasciulli, M. E. D. Flowers, A. Tichelli, J. E. Sanders, H. J. Deeg, and G. Socie
Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-Late Effect Working Party
Blood, January 15, 2008; 111(2): 939 - 944.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. L. De Bruin, J. Huisbrink, M. Hauptmann, M. A. Kuenen, G. M. Ouwens, M. B. van't Veer, B. M. P. Aleman, and F. E. van Leeuwen
Treatment-related risk factors for premature menopause following Hodgkin lymphoma
Blood, January 1, 2008; 111(1): 101 - 108.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.